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1 INTRODUCTION 
 
In the fields of biotechnology and analytical chemistry there is an increasing need for 
new, more efficient, cheaper and less time-consuming methods of analysis. Among the 
various applications of these methods is the field of drug development: better analytical 
methods may help reduce the increasing costs of drug development, eventually 
contributing to faster and more effective innovation of new pharmacotherapies. 
Miniaturized techniques are increasing in popularity due to their reduced reagent and 
solvent consumption, and potential for rapid analysis of large amounts of compounds 
(Whitesides 2006). In addition, cheap and disposable miniaturized platforms eliminate 
the carry-over effects that can be cumbersome in traditional larger scale methods. 
 
This MSc (Pharm) thesis consists of two parts, the literature review and the 
experimental section. In the literature review, the topics to be discussed are general 
properties and applications of microfluidic systems, and acoustofluidics. In addition, 
brief background information is provided about serotonin transporter in platelets, 
MALDI mass spectrometry, and screening of cell-drug interactions. The experimental 
section describes the development of a new nanobiotechnology platform for mass 
spectrometric screening of cell-drug interactions using acoustic trapping. The 
miniaturized solid phase extraction procedure for the analytes to be used was optimized, 
and the performance of the acoustic trapping setup was assessed and modelled. The 
suitability of the platform was studied by investigating the interaction of selective 
serotonin reuptake inhibitor (SSRI) drugs fluoxetine and citalopram with their 
molecular target, the serotonin transporter, in human platelets and cell membranes from 
cells overexpressing serotonin transporter. A comparative SSRI binding assay was 
performed without using acoustic trapping. 
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2 LITERATURE REVIEW 
 
2.1 Microfluidics and lab-on-a-chip systems 
 
Microfluidics can be defined as “the science and engineering of systems in which fluid 
behavior differs from conventional flow theory primarily due to the small length scale 
of the system” (Fundamentals and Applications of Microfluidics 2006). Fluidic systems 
in microscale have unique physical characteristics compared to corresponding systems 
of conventional size, and thus microfluidics is not only about miniaturization of 
systems, but as well investigation and understanding of these microscale phenomena. 
Naturally, the understanding of the physics of microscale flows will improve the design 
and fabrication of microsystems. 
 
The introduction of the fabrication technology called silicon micromachining in the 
mid-20
th
 century and the subsequent revolutionary advance in microelectronics have 
paved the way for the application of miniaturization in various other contexts, one of 
which is microfluidics (Fundamentals and Applications of Microfluidics 2006). Other 
major factors contributing to the rise of microfluidics are the efficiency of miniaturized 
methods in chemical and biological analyses, and the development of portable devices 
for the detection of chemical and biological warfare agents (Whitesides 2006). 
Currently, microfluidic devices can be found in various fields and technologies, 
including chemical synthesis and analysis, as well as in countless applications in life 
sciences. Some of these applications are reviewed in the following chapter. Today, 
microfluidics is a major interdisciplinary field covered in many specialized journals, 
such as Microfluidics and Nanofluidics, Lab on a Chip and Biomicrofluidics, as well as 
international conferences. In addition, articles involving microfluidics are frequently 
published in numerous major scientific journals. 
 
Characteristically for an emerging multidisciplinary field, the terminology used in 
microfluidics is broad, and occasionally inconsistency and confusion tend to occur. The 
following terms are associated with microfluidic technology in general; more specific 
terms used will be covered in concerning sections. The term microelectromechanical 
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systems (MEMS) refers to “devices that have characteristic length of less than 1 mm but 
more than 1 micron, that combine electrical and mechanical components and that are 
fabricated using integrated circuit batch-processing technologies” (Gad-el-Hak 1999). 
MEMS is commonly used to describe various kinds of microtechnology, but some argue 
that the limitation is that besides electrical and mechanical, it does not include any other 
techniques used, such as fluidics and optics (Fundamentals and Applications of 
Microfluidics 2006). A better umbrella term would thus be microsystem technology 
(MST). Sometimes nanofluidics, describing fluid flows in nanoscale, is considered as its 
own, separate field (Eijkel 2009). However, microfluidics can be thought to include also 
nanofluidics (Fundamentals and Applications of Microfluidics 2006). The term µTAS 
(miniaturized total chemical analysis system) was first used in 1990, referring to a total 
chemical analysis system performing all the sample handling steps in the immediate 
vicinity of the measurement (Manz et al. 1990). While µTAS only refers to analytical 
applications, the term lab-on-a-chip (LOC) is used for any kind of laboratory processes 
executed on a microfabricated chip. 
 
As stated in the above definition of microfluidics, the fluid behavior in microscale 
differs fundamentally from that of macroscale systems. The mobile phase can be either 
liquid or gas, and even some supercritical fluid applications have been reported and 
reviewed (Marre et al. 2012). Due to the nature of the experimental section of this 
thesis, the main focus is on liquid systems. For liquids in microchannels, it is justified to 
assume liquid incompressibility, and the descriptions in the following chapters rely on 
that assumption (Squires and Quake 2005). 
 
In fluid mechanics, it is common to make the continuum assumption: the fluid is 
considered as a continuum, indefinitely divisible, and its characteristics are assumed to 
change continuously between different points of the fluid flow (Gad-el-Hak 1999). The 
continuum assumption is indeed applicable for most situations in microfluidics, and 
consequently the laws of conservation of mass, momentum and energy can be used for 
the modeling of those situations. The partial differential equations called Navier-Stokes 
equations are the mathematical description of the flow behavior, and thus these 
  
4 
 
equations can be used in the estimation of the applicability of the continuum 
assumption. 
 
However, when the size range of the fluid channels is decreased enough (generally 
below 10 nm), the continuum assumption tends to fail due to the channels being not 
wide enough to contain enough fluid molecules for continuous behavior (Squires and 
Quake 2005). In such situations, the intermolecular variations of fluid properties 
become significant relative to the size scale of the apparatus. Such deviation from the 
continuum assumption occurs also in the presence of high shear rates, when the 
Newtonian behavior of fluids becomes disturbed (Loose and Hess 1989). It is notable 
that the larger the molecular mass of the fluid, the lower shear rates are required for this 
phenomenon to occur. The applicability of the continuum assumption requires also that 
the system is sufficiently close to thermodynamic equilibrium (Gad-el-Hak 1999). In 
such cases of continuum assumption failure, molecular approaches are needed: instead 
of a continuum, the fluid is treated as a collection of molecules interacting with the 
channel walls and each other. In modeling, this obviously leads to more accurate results, 
since the fluid is modeled as it really is. However, modeling the velocities, locations and 
collisions of all fluid molecules separately makes the modeling process more 
complicated, and thus the molecular approach requires more computing power. 
 
Boundary conditions are assumptions about the behavior of the fluid flow in the 
immediate vicinity of an interface with another phase, usually a channel wall (Gad-el-
Hak 1999). Due to interactions between the fluid and the wall, altered fluid behavior in 
the terms of temperature, velocity and pressure can be expected near the wall. In 
systems of conventional size, it is commonly assumed that the fluid temperature, 
velocity and pressure right next to the wall equal those of the wall. Treating the fluid as 
a continuum leads to these assumptions: the characteristics change continuously within 
the fluid, and there is no reason to assume that the molecular interactions between two 
fluid particles radically differ from the same interactions between fluid particles and the 
channel wall; consequently, no discontinuity of those characteristics can occur between 
the fluid and the channel wall. 
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In microfluidic liquid applications, it can be expected that the large surface-to-volume 
ratio may cause confusion in the application of boundary conditions: the first two 
boundary conditions describing temperature and pressure are nevertheless valid in most 
of the cases, as the system size is still sufficiently large for the continuum assumption 
(Squires and Quake 2005). However, the failure of continuum assumption, i.e. the non-
Newtonian behavior of fluid, leads to the inapplicability of the boundary condition 
describing fluid velocity, known as the no-slip boundary condition. For liquids, this 
happens e.g. in situations of high shear rate (Loose and Hess 1989), corner flows 
(Moffatt 1964) and the presence of two immiscible fluids on a solid surface (Thompson 
and Robbins 1989). 
 
The most characteristic property of microscale flows is laminarity: the viscous forces 
dominate over inertial forces in the fluid (Squires and Quake 2005). As a result, no 
turbulence occurs, and the fluid flow has no velocity parallel to the channel. The most 
common parameter for the flow laminarity is the Reynolds number, defined as the ratio 
of inertial and viscous forces in the fluid: 
 
Re =
𝑓𝑖𝑛𝑒𝑟𝑡𝑖𝑎𝑙
𝑓𝑣𝑖𝑠𝑐𝑜𝑢𝑠
=
𝜌𝑈0𝐿0
𝜂
 
 
in which ρ stands for the density of the fluid, L0 for the typical length scale of the 
system, U0 for the velocity of the fluid movement and η for the shear viscosity of the 
fluid (Squires and Quake 2005). The borderline Reynolds number between laminar and 
turbulent flow depends on the fluid characteristics, but is generally between 2000 and 
3000. Flows with low Reynolds numbers are laminar, and they are known as Stokes 
flows. It is notable that calculations of Reynolds number assume negligible gravity. The 
laminarity makes the flow behavior predictable, and enables unique applications, such 
as those utilizing parallel flows of immiscible liquids, between which solute exchange 
occurs via diffusion, in a single channel. On the other hand, the laminar flow has to be 
taken into account in cases such as mixing, which happens entirely by diffusion in the 
absence of turbulence. 
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The no-slip boundary condition leads to the typical flow profile of a fluid flow in a 
microchannel, which occurs also in cases in which slip takes place: since the fluid 
velocity at the immediate vicinity of the channel walls is zero or extremely small, there 
must be a velocity gradient present in the fluid flow (Squires and Quake 2005). The 
means of inducing the flow affects the flow profile in straight channels: for pressure-
driven flow (Poiseuille flow) it is parabolic and for electro-osmotic flow flat (Figure 1). 
The difference in flow profiles has its effect on e.g. separation science, in which the 
parabolic flow profile is a known source of band broadening (Kutter and Welsch 1995). 
The effect responsible for this is known as Taylor dispersion (Taylor 1953, 1954). The 
same effect can be exploited in mixing applications (Chou et al. 2001). 
 
 
Figure 1: The fluid flow profiles in a microfluidic channel. a) pressure-driven flow; b) 
electro-osmotic flow. 
 
Another typical characteristic of microfluidic systems is high surface-to-volume ratio, 
arising from the small size of the fluid channels (Fundamentals and Applications of 
Microfluidics 2006). In the contact surfaces between the fluid and the microchannel 
walls, the significance of surface tension is larger compared to macroscale systems. 
This results in capillary force being an important effect which can be greatly influenced 
by the choice of surface materials and surfactants. The surface tension can also be 
altered by electric fields (Lippmann 1875), in a process called electrowetting (Beni and 
Hackwood 1981). The increased importance of surface forces makes the use of 
electrokinetic techniques suitable for moving fluids and particles in microfluidic 
systems (Fundamentals and Applications of Microfluidics 2006). 
 
When the distances within the fluid are small, the importance of diffusion is bigger 
(Manz et al. 1990). This can be both an advantage and a disadvantage: on the one hand, 
e.g. reactive species can be easily brought together and Brownian motion of particles 
can be used for temperature measurements (Chung et al. 2009), and the different 
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diffusion properties of molecules utilized in separation (Chou et al. 2000). On the other 
hand, Brownian motion can also be a source of uncertainty when measurements with 
tracer particles are done (Olsen and Adrian 2000). 
 
A wide variety of materials and techniques is used for the fabrication and manufacture 
of microsystems (Chanmanwar et al. 2013). The intended purpose and desired outcome 
of the system to be produced affect the choice of material, and all these factors 
contribute to the choice of fabrication technique (Bruzzone et al. 2008). The differences 
in elasticity and chemical stability of materials are frequently utilized in the 
manufacture of microsystems through the use of molding masters as well as sacrificial 
and stable material layers. The materials available include glass, different forms of 
silicon, metals, a variety of polymers, and ceramics. An important property of the 
microfabrication technique used is resolution, which determines the possible size range 
and the finishing quality of the product. In small channels, minor changes in channel 
shapes can greatly influence the fluid flow properties within the channel. The objective 
is to make ideal-shaped channel systems with high speed and repeatability. 
 
A wide variety of microfluidic applications exists, discussed in detail both in books and 
review articles (Fundamentals and Applications of Microfluidics 2006, Squires and 
Quake 2005, Whitesides 2006). Different microfluidic modules are often combined to 
form more complicated lab-on-a-chip systems. Numerous advantages are characteristic 
to the microfluidic applications: portability helps to bring the technology where 
conventional systems can’t be taken, and lower consumption of chemicals and energy 
decreases both the environmental burden and the price of operation. Given the 
possibility of affordable mass production, the price of the systems can be very low. The 
unique physical phenomena of microscale fluid behavior can be used of benefit, but on 
the other hand, they make the scaling-down of systems more challenging. Especially the 
connections between microscale and macroscale are particularly tricky: e.g. the 
significance of dead volumes increases. Narrow channels are more prone to suffer from 
clogging and bubble formation, and it may be difficult to combine several electrical 
instruments on a single chip without electrical disturbances. 
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The examples of applications of microfluidic systems in analytics include sampling 
(Tesař 2001), sample preparation (Fritz and Masso 2001), separation (Erxleben and 
Ruzicka 2005) and detection (O’Toole et al. 2006), as well as combinations of these 
(Cakal et al. 2010). Disposability of analytical devices decreases the risk of 
contamination (Ricco et al. 2002). Analysis with high sensitivity and resolution can be 
achieved using only minuscule amounts of samples, solvents and reagents (Whitesides 
2006). Given the short fluidic distances, the microfluidic analysis is also very fast. The 
present and potential future applications of microfluidic analytic devices include the 
detection of biomarkers in diagnostics, the field of drug development, and scientific 
research in general, especially in the life sciences. 
 
Besides applications in biochemical analysis in life sciences, microfluidic systems can 
be used in cell handling and cell cultures (Walker et al. 2004). The size of the systems is 
suitable for cells, and allows the modification of the microenvironment to produce more 
in vivo –like conditions. This has the potential to improve the in vitro – in vivo 
correlation of cell experiments. In a technology called organ-on-a-chip, cells are 
implemented on a specifically designed microchip, which is used to model the function 
of human organs (Polini et al. 2014). Models of separate organs can be combined into a 
model of entire organism, sometimes referred to as human-on-chip (Luni et al. 2014). 
Microfluidic devices are suitable also for chemical synthesis, protein crystallization and 
production of emulsions and foams (Whitesides 2006). 
 
2.2 Acoustofluidics 
 
It has long been known that acoustic fields exert forces on particles (King 1934). The 
term acoustofluidics refers to “ultrasound-based external forcing of microparticles in 
microfluidics” (Bruus 2011). This umbrella term includes different techniques, such as 
acoustophoresis and acoustic trapping, as well as their applications. Acoustophoresis is 
the moving of particles using acoustic waves, whereas acoustic trapping involves the 
immobilization of particles (Evander and Nilsson 2012). An excellent 23-part tutorial 
series on the topic of acoustofluidics has been published in Lab on A Chip in the years 
2011-2013. 
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The first reference available on the technique of acoustic trapping dates back to 1996 
(Lierke 1996). The technique involves an acoustic standing wave in a fluid-filled 
microchannel, generated by ultrasound of appropriate frequency, which depends on the 
measures of the channel (Evander and Nilsson 2012). The relation of channel width or 
height (x), frequency (f), speed of sound in the fluid medium (v), the wavelength of the 
sound (λ) and number of pressure nodes (n) is presented in the equation below. In most 
cases, a frequency generating one pressure node is used, leading to one cluster of 
acoustically trapped particles in the center of the microchannel (Figure 2). 
 
𝑥 = 𝑛
𝑣
2𝑓
= 𝑛
𝜆
2
 
 
 
Figure 2: Illustration of the principle of acoustic trapping. Microparticles are trapped in 
the pressure node of the acoustic standing wave, generated in a microchannel by a 
piezoelectric transducer. Acoustic streaming causes vortical fluid movement around the 
cluster of trapped particles. 
 
Points of acoustic potential minima and maxima are generated in the fluid by the 
acoustic standing wave. The objects, depending on the density and compressibility of 
themselves and the fluid medium, move either to these minima or maxima (Evander and 
Nilsson 2012). In water-based medium, cells and microparticles are typically gathered 
to the acoustic potential minima i.e. the pressure nodes. This is due to the fact that the 
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cells and particles usually have higher density and lower compressibility relative to 
water.  
 
The forces moving the particles into the acoustic trap and keeping them trapped are 
called acoustic radiation forces (Evander and Nilsson 2012). The acoustic waves 
scattering on the particles are responsible for the force (Bruus 2012). For a particle in a 
fluid medium, the primary acoustic radiation force (F
rad
) can be calculated using the 
following equations: 
 
𝐹𝑟𝑎𝑑 = −∇𝑈𝑟𝑎𝑑 
 
𝑈𝑟𝑎𝑑 =
4𝜋
3
𝑎3 [𝑓1
1
2
𝜅0〈𝑝𝑖𝑛
2 〉 − 𝑓2
3
4
𝜌0〈𝑣𝑖𝑛
2 〉] 
 
𝑓1(?̃?) = 1 − ?̃?, ?̃? =
𝜅𝑝
𝜅0
 
 
𝑓2(?̃?) =
2(?̃? − 1)
2?̃? + 1
, ?̃? =
𝜌𝑝
𝜌0
 
 
in which U
rad
 is the acoustic potential, a is the radius of the particle, κ0 is the 
compressibility of the fluid, ρ0 the density of the fluid, κp is the compressibility of the 
particle, ρp is the density of the particle, pin is the incoming pressure field and vin the 
incoming velocity field (the chevrons are used to indicate time average). Certain 
conditions are assumed: the particle is spherical with a radius significantly smaller than 
the wavelength of the standing wave, and the fluid is inviscid. A more thorough 
description of acoustic radiation force, including mathematical analyses and derivations, 
is presented earlier by Bruus (2012).  
 
The description above concerns the situation of one particle in an acoustic field in a 
fluid medium. When there are two or more particles present, the acoustic waves 
scattered from the particles cause secondary acoustic radiation forces (Gröschl 1998). 
For particles residing in the acoustic trap, the forces are attractive, and thus contribute in 
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keeping them trapped. The secondary acoustic radiation forces, along with the lateral 
component of the primary acoustic radiation force, are the most significant forces 
resisting the force exerted on the particle by the fluid flow, known as Stokes’ drag 
(Evander and Nilsson 2012). The magnitude of Stokes’ drag on the particles depends on 
the particle radius and the flow rate of the fluid medium. 
 
An important effect in acoustic trapping is the effect of acoustic streaming, introduced 
by Faraday in 1831 and in more detail described by Lord Rayleigh in 1884. In principle, 
the phenomenon occurs when the acoustic standing wave is attenuated by the viscosity 
of the fluid, a process in which energy is transferred to the fluid, generating movement 
in the fluid (Sadhal 2012, Wiklund et al. 2012). From the viewpoint of acoustic 
trapping, it is notable that acoustic streaming will create fluid vortices around the cluster 
of trapped particles (Figure 2). 
 
As a relatively new branch of microfluidics, acoustofluidics is applied mainly in 
research, and commercial applications are not yet taken into frequent use. Numerous 
proof-of-concept publications demonstrate the potential of acoustofluidics as a 
technique suitable for a wide range of procedures. An acoustophoretic microchip has 
been successfully used to separate lipids from blood, a procedure that can be applied in 
cardiac surgery (Jönsson et al. 2004, Petersson et al. 2004, 2005). Examples of other 
applications include sample preparation (Norris et al. 2009), bioassays (Evander et al. 
2007), and 3-dimensional cell cultures (Bazou et al. 2008). 
 
2.3 Serotonin transporter in platelets 
 
Serotonin, or 5-hydroxytryptamine (5-HT), is a neurotransmitter involved in a wide 
variety of functions in human body (Aghajanian and Sanders-Bush 2002). In addition to 
the importance of serotonin neurotransmission in the central nervous system and the 
gastrointestinal tract, it has major significance in the cardiovascular system as well, 
where it controls e.g. the vascular tone and platelet aggregation (Mercado and Kilic 
2010). Elevated serotonin levels in blood are found in several cardiovascular diseases. 
Serotonin transporter (SERT), the primary target of many antidepressant drugs, is also 
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expressed on the plasma membranes of platelets, where it is structurally identical and 
genetically similar to the SERT in the central nervous system (Lesch et al. 1993). In 
platelets, the main function of SERT is to regulate the serotonin concentration in blood 
(Mercado and Kilic 2010). 
 
Due to the similarity of SERT in platelets and central nervous system, platelets have 
been suggested to be used as a model for the function of serotonergic neurons (Da Prada 
et al. 1988). The suitability of the model has been studied by e.g. Uebelhack et al. 
(2006), but no explicit correlation between the serotonin uptake to platelets and its 
partitioning in the midbrain could be proven. Also the suitability of platelet SERT as a 
biomarker for illnesses such as such as obesity, epilepsy and depression has been 
investigated (Giannaccini et al. 2013, Cupello et al. 2008, Alvarez et al. 1999). The 
platelet SERT biomarker studies and their success have been reviewed by Yubero-
Lahoz et al. (2013). 
 
2.4 MALDI mass spectrometry 
 
Matrix assisted laser desorption/ionization (MALDI) is an ionization technique for mass 
spectrometry, first referred to by Karas et al. (1985). Soon after, the technique was 
proven capable of ionizing large biomolecules intact (Karas and Hillenkamp 1988). 
Today, MALDI MS is a standard tool for the analysis of biological macromolecules, 
and also used sometimes in microfluidic applications (Lee et al. 2009). In 2002, one half 
of the Nobel Prize in chemistry was jointly awarded to Koichi Tanaka (MALDI MS) 
and John B. Fenn (ESI MS) for their work in the field of biological mass spectrometry. 
 
In MALDI, the sample to be analyzed is mixed and co-crystallized on a sample plate 
with an organic compound called the matrix, and a pulsed laser beam is focused on the 
sample plate (Proteomics in Practice 2008). The matrix compound is chosen so that it 
absorbs light at the wavelength of the laser in use, thus leading to desorption and 
ionization of the matrix compound. The co-crystallized analytes are also desorbed from 
the sample plate along with, and ionized by, the matrix compound (Figure 3). Many of 
the commonly used matrix compounds are cinnamic acid derivatives, particularly α-
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cyano-4-hydroxycinnamic acid (CHCA), but also basic compounds can be used 
(Fitzgerald et al. 1993). The desorption and ionization mechanisms in MALDI are 
complex processes, and especially for the ionization, multiple mechanisms have been 
suggested (Knochenmuss 2006). MALDI is predominantly operated under vacuum, but 
atmospheric pressure applications exist as well (Laiko et al. 2000). 
 
 
Figure 3: The MALDI MS process. A pulsed laser beam is used to desorb and ionize the 
co-crystallized analytes and matrix from the MALDI sample plate, followed by mass 
spectrometric analysis. 
 
2.5 Screening of cell-drug interactions 
 
The in vitro screening of cell-drug interactions, including both ligand binding assays on 
receptors and studies on the effects of drugs on cell cultures of viable cells, is vital for 
drug discovery and development (de Jong et al. 2005). Simple, reliable and fast methods 
capable of high-throughput screening (HTS) are required to scan through large chemical 
libraries in order to find molecules with desired pharmacological activity. In these 
assays, the detection can be done directly on the receptor-ligand interaction, a secondary 
messenger released as a consequence of the ligand binding to the receptor, or a 
functional cellular response to the receptor activation or deactivation. 
 
For the investigation of a ligand binding to a receptor, the typical procedure is to label 
the ligand with a chemical entity enabling detection (Sittampalam et al. 1997). 
Commonly used labeling compounds contain either radioisotopes or fluorophores, 
detected by scintillation or fluorescence, respectively. Labeling a compound may, 
however, change the properties of the compound. In addition, high price and heavy 
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workload, and in the case of radioligand labeling, the safety issues, are characteristic of 
labeling techniques. For these reasons, label-free methods, such as surface plasmon 
resonance (SPR) and mass spectrometry (MS), are attractive alternatives to the labeling 
techniques (de Jong et al. 2005). 
 
The typical binding assay involves exposing the target receptor to the test compound, 
the subsequent washing and elution steps (if necessary), and finally, detection (de Jong 
et al. 2005). The receptor can be in the form of organ tissue sections, whole viable cells, 
cell membrane preparations, or as such, produced by recombinant DNA technique. 
Specific receptor-ligand binding has to be differentiated from nonspecific binding of the 
ligand to the cell membranes. This can be done either by removing the nonspecifically 
bound ligand by suitable washing, or by quantifying the nonspecific binding, e.g. by 
using in excess another ligand for the target receptor, as done by e.g. Hess et al. (2011). 
 
2.6 Aim of the study  
 
In this MSc (Pharm) thesis, the performance of a new nanobiotechnology platform for 
the screening of cell-drug interactions was investigated. The system used involved 
acoustic trapping of cells in a borosilicate glass capillary with an ultrasonic standing 
wave generated by a piezoelectric transducer (Figure 2). This enabled the exchange of 
fluid medium in the capillary, with the cell cluster remaining stationary, which in turn 
permitted rapid aspiration and dispensing of sample solutions and eluents. Acoustic 
streaming (Figure 2) around the trapped cell cluster was expected to enable adequate 
fluid exchange (i.e. efficient washing) and the transport of sample to the close proximity 
of the cells. A membrane preparation from cells overexpressing serotonin transporter 
(SERT), used in typical ligand binding assays, and human platelets were used to screen 
the binding of the selective serotonin reuptake inhibitor (SSRI) compounds fluoxetine 
and citalopram to SERT. Prior to mass spectrometric analysis, the samples were 
subjected to solid-phase extraction using the Integrated Selective Enrichment Target 
(ISET, Figures 6 and 7), a miniaturized solid phase extraction method developed by 
Ekström et al. (2004, 2006). The analysis was done by MALDI MS (Figure 3), allowing 
the label-free detection of the analytes. 
  
15 
 
The experimental work started with the optimization of the ISET sample preparation for 
the analytes, after which the trapping capacity of the acoustic trap was investigated by 
trapping polystyrene beads and counting them with a Coulter counter. The system 
performance was modeled and the procedure optimized by trapping strong cation 
exchange (SCX) beads and incubating them with the analytes, followed by ISET sample 
preparation and MALDI MS analysis. After this, the binding assays using acoustic 
trapping, ISET sample preparation, and MALDI MS, were conducted with platelets, 
yeast cells (intended to be used as a model for nonspecific binding), and the cell 
membrane preparation from cells overexpressing SERT. Finally, a comparative mass 
spectrometric SSRI binding assay to the SERT in the cell membrane preparation was 
conducted without using acoustic trapping. 
  
  
16 
 
3 EXPERIMENTAL SECTION 
 
3.1 Materials and methods 
 
3.1.1 Chemicals 
 
Water was purified with Milli-Q water purifying system (Millipore, Molsheim, France). 
Analysis grade hydrochloric acid, glycine, potassium chloride and Triton-X-100 were 
purchased from Merck KGaA (Darmstadt, Germany); analysis grade 25 % ammonia 
and ≥99 % sodium chloride from VWR International (Fontenay-sous-Bois, France); all 
other chemicals, LC-MS or HPLC grade when available, were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). The manufacturers of other materials and equipment 
used are stated in the corresponding chapters. 
 
The compounds fluoxetine, deuterium labeled fluoxetine (fluoxetine-D5), citalopram, 
and serotonin (5-HT) were used as analytes for the experiments. Their chemical 
structures and monoisotopic masses are presented in Figure 4. These compounds were 
supplied as hydrochloride salts, except citalopram, which was as hydrobromide salt. 
 
 
Figure 4: The analytes used in the experiments, and the corresponding monoisotopic 
masses. 
 
3.1.2 Sample preparation optimization 
 
For sample preparation, the Integrated Selective Enrichment Target (ISET) platform 
was used; the system is described in detail elsewhere (Ekström et al. 2004, 2006). The 
platform consists of 95 pyramid-shaped nanovials on a silicon plate with thickness of 
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780 µm (Figure 5). At the tip of each pyramid-shaped nanovial, 9 quadratic holes, each 
20×20 µm, provide an opening to the other side of the plate (Figure 5). The plates are 
fabricated by chemical wet etching and deep reactive-ion etching. 
 
The ISET platform is suitable for various kinds of procedures, such as solid phase 
extraction (SPE) and protein digestion (Ahmad-Tajudin et al. 2014). The ISET SPE 
procedure (Figure 6) involves transferring solid phase beads into the nanovials with the 
suction provided by a vacuum pump (Vacuubrand GMBH, Wertheim, Germany), before 
or after introducing the beads to the sample which is to be subjected to SPE (Adler et al. 
2012). The procedures are called direct ISET and indirect ISET, respectively (Figure 7). 
After this, the impurities are eluted (washed) and the plate bottom dried, followed by 
the elution of analytes. Suitable eluents are chosen according to the solid phase used. As 
the result of the elution, the analytes are co-crystallized and concentrated within the 
crystallized matrix around the nanovial outlet on the bottom side of the ISET platform, 
allowing direct MALDI MS analysis (Figure 6). Throughout the experiments, MS grade 
α-cyano-4-hydroxycinnamic acid (CHCA) was used as the matrix compound. 
 
 
Figure 5: a) the ISET platform; b) close-up microscope image of a nanovial, showing 
the bead retaining grid at the bottom of the nanovial. The volume of a single nanovial is 
600 nL. 
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Figure 6: The SPE sample preparation procedure on the ISET platform. The sample is 
introduced to the beads already present in the nanovial (direct ISET), followed by 
washing away the impurities and the elution of the analytes. The analytes are co-
crystallized with the matrix around the outlet, allowing direct MALDI MS analysis. 
Figure reprinted with permission from Ekström et al. 2006. 
 
 
Figure 7: The ISET sample preparation procedure. a) direct ISET, in which the solid 
phase beads are transferred into the ISET plate before the introduction of the sample; b) 
indirect ISET, in which the solid phase beads are incubated with the sample solution 
prior to transferring into the ISET plate. 
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Experiment A. The performance of Poros R1 50 (C4 phase 50 µm) and Poros R2 50 
(phenyl phase 50 µm) solid phase beads (Applied Biosystems Inc., Foster City, CA, 
USA) in direct ISET sample preparation of fluoxetine and fluoxetine-D5 was 
investigated. The sample solutions were prepared in 0.1 % TFA (trifluoroacetic acid) in 
MQ water and contained equal concentrations of fluoxetine and fluoxetine-D5, ranging 
from 0.25 to 50 µmol/L. 5 mg/mL CHCA in 60 % acetonitrile (ACN) was used as the 
matrix solution. The ISET sample preparation was done according to the procedure 
below. For liquid transport through the ISET, vacuum of 5 lnHg was used at phases 1-3 
and 1.5 lnHg at phases 5-6. 
 
1. Transferring solid phase beads into the nanovials. 
2. Introducing 1 µL of the sample solution into the nanovials. 
3. Washing with 2.5 µL of 0.1 % TFA. 
4. Drying the ISET plate bottom with a laboratory wipe. 
5. Elution with 0.5 µL of the matrix solution. 
6. Drying for 15 minutes. 
 
Experiment B. In addition to the direct ISET sample preparation presented above, 
indirect ISET sample preparation was tested: both R1 and R2 beads were preincubated 
with the sample prior to transferring onto the ISET plate. 15 µL of the sample and 10 
µL of 20 mg/ml bead suspension were used, the incubation time being 45 minutes. After 
the incubation, 2.5 µL of the incubated suspension was transferred onto the ISET plate, 
the sample volume per nanovial being approximately equal to that of the corresponding 
experiments without incubation. Washing with was done like in experiment A, but to 
improve crystallization, two elutions with 30 minutes drying time in between were used. 
 
After the ISET procedure, the samples from experiments A and B were analyzed with a 
Waters M@LDI-TOF MS mass spectrometer (Milford, MA, USA) with a 337 nm 
nitrogen UV laser, operated in reflector mode. The MALDI settings were optimized 
before data acquisition. The accumulated spectra of 100 laser shots were acquired per 
sample spot. Before reusing, the ISET plates were washed according to the following 
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procedure. The same procedure was used for ISET cleaning throughout all of the 
experiments. 
 
1. Removing beads and crystals with a paintbrush under running tap water. 
2. Cleaning with ethanol using a paintbrush. 
3. Cleaning with MQ water using a paintbrush. 
4. 2-propanol bath for 20 minutes. 
5. Acetonitrile bath for 20 minutes. 
 
3.1.3 Piezoelectric transducer testing and acoustic trapping capacity 
 
The acoustic trapping setup used (Figure 8) consists of a piezoelectric transducer 
(Ferroperm Piezoceramics A/S, Kvistgaard, Denmark) on a microchip, placed on a 
plastic mount. A borosilicate glass capillary (VitroTubes, VitroCom, Mountain Lakes, 
NJ, USA) of the volume 20 µL, length 50 mm and external thickness 0.51 mm is 
connected to Tygon tubings (Saint-Gobain S.A., Courbevoie, France) with optical 
adhesive (Norland Products, Inc., Cranbury, NJ, USA). The capillary is placed on top of 
the transducer and tightened in place with a plastic holder. A glycerol film is used 
between the capillary and the transducer for acoustic coupling. A function generator 
(33120A, Agilent Technologies Inc., Santa Clara, CA, USA) is used to control the 
piezoelectric transducer; with a LabVIEW 2013 (National Instruments Corporation, 
Austin, TX, USA) frequency tracking software programmed in-house (Hammarström et 
al. 2014). The fluid flow in the capillary is controlled by a syringe pump (cetoni GmbH, 
Korbußen, Germany) with a 1 mL gastight syringe (Hamilton Bonaduz AG, Bonaduz, 
Switzerland). In all experiments, the fluids were aspirated into the capillary from an 
Eppendorf tube cap. 
 
Experiment C. 13 piezoelectric transducers, numbered #1 to #13, of a similar model 
were tested for their ability to hold 10 µm polystyrene beads (Sigma-Aldrich Co., St. 
Louis, MO, USA) in the acoustic trap with different flow rates (Figure 9). Flow rates 
ranging from 10 to 250 µL/min, with the intervals of 10 µL/min, were used, with MQ 
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water as the fluid medium. Microscope images were captured throughout the process. 
The overall procedure was as follows: 
 
1. Trapping a cluster of beads by aspirating 10 µL of bead suspension (0.05 % m/V 
in MQ water) with the flow rate 50 µL/min. 
2. Transferring non-trapped beads through the trapping site by aspirating 20 µL of 
MQ water with the flow rate 50 µL/min. 
3. Stabilizing the amount of trapped beads by dispensing 30 µL of the fluid 
medium with the flow rate 10 µL/min. 
4. Gradually increasing the flow rate until the bead cluster exits the trap. 
 
 
Figure 8: The acoustic trapping setup. a) capillary glued to tubing; b) piezoelectric 
transducer; c) plastic holder; d) the acoustic trapping setup on the plastic mount. 
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Figure 9: A microscope image of a small cluster of 10 µm polystyrene beads in the 
acoustic trap. 
 
Experiment D. In order to estimate the sensitivity that can be achieved with the system, 
the trapping capacity of transducers #1, #5 and #8 was further investigated using 3 µm 
polystyrene beads (Sigma-Aldrich Co., St. Louis, MO, USA), which are approximately 
of the same diameter as human platelets (Paulus 1975). Flow rates of 20, 40, 60, 80 and 
100 µL/min were used, with triplicate measurements for each flow rate. To avoid the 
adherence of the beads to capillary and container walls, 0.1 % Triton-X-100 in MQ 
water was used as the detergent to prevent bead aggregation and sticking to the walls. 
However, the syringe was filled with MQ water only, in order to avoid detergent 
contamination and carry-over effects in further experiments. The procedure was as 
follows: 
 
1. Trapping a cluster of beads by aspirating 150 µL of bead suspension (1.25×107 
beads/mL in 0.1 % Triton-X-100) with the flow rate 50 µL/min. 
2. Stabilizing the amount of trapped beads by dispensing 150 µL of the fluid 
medium with the specified flow rate. 
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3. Turning off the acoustic trap. 
4. Transferring the beads into an Eppendorf tube by dispensing 20 µL of the fluid 
medium with the flow rate 50 µL/min. 
5. Adding 160 µL of 0.1 % Triton-X-100 in MQ water into the Eppendorf tube. 
6. Adding 20 µL of bead suspension (1.25×107 beads/mL in 0.1 % Triton-X-100) 
into the Eppendorf tube. 
 
A volume of 0.1 % Triton-X-100 in MQ water equal to the volume dispensed from the 
trap was used as the blank. Adding the bead suspension to the samples in phase 6 
allowed the comparison of bead concentrations by subtraction. The sample bead 
suspensions were diluted into 100 mL of 0.9 % sodium chloride solution for Coulter 
counting with Multisizer 3 Coulter counter (Beckman Coulter Inc., Pasadena, CA, 
USA) using a 100 µm aperture. Triplicate measurements were made for each sample, 
and the amounts of trapped beads were calculated. 
 
3.1.4 Experiment with strong cation exchange beads 
 
Experiment E. In order to test the acoustic trapping system performance and optimize 
the procedure, 1 µm Dynabeads® strong cation exchange (SCX) beads (Invitrogen 
Dynal AS, Oslo, Norway) were incubated in-trap with sample solutions containing 
equal concentrations of fluoxetine and fluoxetine-D5, ranging from 5 to 50 µmol/L. The 
bead suspension and sample solutions were made in MQ water containing 0.1 % TFA, 
and the same solution was used as the fluid medium. Transducer #8 was used, and the 
flow rate was 20 µL/min. The eluent used was 30 % methanol, 5 % ammonia in MQ 
water. After dispensing the eluent, also the strong cation exchange beads were 
dispensed from the trap along with 20 µL of fluid medium, in order to investigate the 
efficiency of the elution. The following procedure was utilized: 
 
1. Trapping a cluster of beads by aspirating 100 µL of 0.2 mg/mL bead suspension. 
2. Stabilizing the amount of trapped beads by dispensing 200 µL of the fluid 
medium. 
3. Aspirating 20 µL of sample solution. 
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4. Incubation for 30 minutes. 
5. Removing unbound sample by dispensing 120 µL of the fluid medium. 
6. Aspirating 20 µL of eluent. 
7. Incubation for 30 minutes. 
8. Dispensing 20 µL (eluent) into an Eppendorf tube cap. 
9. Turning the acoustic trap off. 
10. Dispensing 20 µL of the fluid medium, along with the SCX beads, into an 
Eppendorf tube cap. 
11. Rinsing the capillary by dispensing 50 µL of the fluid medium. 
 
1 µL aliquots of the eluent samples and fluid medium aliquots containing the SCX 
beads were pipetted as duplicates onto a MALDI plate for dried droplet analysis and 
2×1 µL of matrix solution (5 mg/mL CHCA in 60 % acetonitrile) was added. The 
samples were analyzed with a Waters M@LDI-TOF MS mass spectrometer (Milford, 
MA, USA) with a 337 nm nitrogen UV laser, operated in reflector mode. The MALDI 
settings were optimized before data acquisition. The accumulated spectra of 100 laser 
shots were acquired per sample spot. 
 
Experiment F. The efficiency of the indirect ISET sample preparation (Figure 7) was 
investigated. Into the remaining 16 µL of eluent or SCX bead residue from experiment 
E, 4 µL of 20 mg/mL Poros R2 50 solid phase bead suspension was added, followed by 
20 minutes incubation. ISET sample preparation as triplicate sample spots was done as 
listed below. For liquid transport through the ISET, vacuum of 5 lnHg was used at 
phases 1-2 and 1.5 lnHg at phase 4. Before the ISET pretreatment, the fluid medium 
aliquots containing the beads dispensed from the trap were basified with 1 µL of 30 % 
methanol, 5 % ammonia prior to incubating for 30 minutes with 2.5 µL of 20 mg/mL 
R2 bead suspension. MALDI MS analysis was done as in experiment E. 
 
1. Transferring 5 µL of sample with R2 beads into a nanovial. 
2. Washing with 2.5 µL of 0.1 % TFA. 
3. Drying of the ISET plate bottom with a laboratory wipe. 
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4. Eluting thrice with 0.5 µL of 5 mg/mL CHCA in 60 % ACN with 15 minutes 
drying time in between. 
 
3.1.5 Drug binding experiments using acoustic trapping 
 
Drug binding studies were done with yeast (Saccharomyces cerevisiae) cells (Kronjäst, 
Jästbolaget AB, Sollentuna, Sweden), human platelets from platelet rich plasma (PRP), 
kindly provided by Prof David Erlinge and colleagues, and cell membrane preparation 
from cells overexpressing human serotonin transporter (“SERT cell membranes”) from 
PerkinElmer (Boston, MA, USA). 0.01 mol/L phosphate buffered saline (PBS) with the 
pH = 7.4 was used as the fluid medium for yeast cells and platelets, and 0.05 mol/L 
Tris-buffered saline (TBS) with the pH = 7.4 for the cell membrane preparation, 
according to the manufacturer’s instructions. The sample solutions were made in the 
fluid medium used. In order to be aspirated into the acoustic trap, the yeast cells were 
suspended in PBS to form a 10 mg/mL suspension. PRP was used as such. In the cell 
membrane preparation, the SERT cell membranes were originally as aggregates in a 
fluid medium, and hence the preparation was diluted with TBS in a ratio 1:7 and 
vortexed before aspirating into the acoustic trap. All experiments were performed both 
with actual drug samples and solvent blank samples. 
 
Since the magnitude of forces actuating acoustic trapping decreases along with the size 
of particles to be trapped, the use of seeding particles to facilitate acoustic trapping of 
small particles or cells may be necessary (Hammarström et al. 2012). The experiments 
described in this chapter were, however, performed without seeding particles. The 
piezoelectric transducer # 8 was used. Figure 10 shows yeast cells, platelets, and SERT 
cell membranes in the acoustic trap. 
 
Experiment G. The yeast cell suspension, PRP, and SERT cell membrane suspension 
volumes required to fill the acoustic trap with cells or cell membranes were 
investigated. Since the operating frequency of acoustic trapping is proportional to the 
speed of sound in the fluid medium, and thus its density, abrupt changes in solvent 
proportions require a change in the operating frequency, and consequently may disrupt 
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the acoustic trapping. Therefore the succeeding of the acoustic trapping of yeast cells 
and platelets during the aspiration of different eluents was investigated. The eluents 
tested were solutions containing different percentages of acetonitrile (ACN) and 
methanol, prepared in 0.1 % TFA in MQ water, 0.5 % TFA in MQ water, and 10 
mmol/L glycine in MQ water acidified to pH ≈ 2 with hydrochloric acid. With the 
SERT cell membranes, the succeeding of the acoustic trapping was tested only with the 
eluent 1:9 ACN:TBS. 
 
 
Figure 10: Acoustically trapped yeast cells (a), human platelets (b), and cell membranes 
(c), also in close-up (d). The cells or cell membranes in the acoustic trap are visible as 
the opaque above the piezoelectric transducer. 
 
Experiment H. Three different eluents were chosen so that effective acoustic trapping 
with both yeast cells and platelets was possible. Their elution efficiency was 
investigated by incubating yeast cells or platelets in the acoustic trap with a sample 
solution containing 50 µmol/L of both fluoxetine and fluoxetine-D5, and eluting with 
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the different eluents. The overall procedure is presented in Figure 11. The following 
eluents were used: 1:9 ACN:PBS, 0.5 % TFA in MQ water, and 10 mmol/L glycine in 
MQ water acidified to pH ≈ 2 with hydrochloric acid. The same experiment was used to 
determine the suitability of yeast cells to be used as a model for nonspecific binding of 
the analytes to the cell membranes. In addition, the same experiment was done with 
platelets using 50 µmol/L citalopram as the sample solution and 1:9 ACN:PBS as the 
eluent. In addition to the eluents and cell residues, also the sample solutions after 
incubation were kept and pretreated, in order to verify the use of right sample solutions. 
The flow rate 20 µL/min was used unless otherwise specified; the trapping procedure 
was as follows: 
 
1. Aspirating 40 µL of yeast cell suspension or PRP. 
2. Stabilizing the amount of trapped cells by dispensing 60 µL of the fluid medium. 
3. Aspirating 20 µL of sample solution. 
4. Incubation for 10 minutes. 
5. Dispensing 20 µL (sample solution after incubation) into an Eppendorf tube cap. 
6. Removing unbound drug by dispensing 60 µL of the fluid medium. 
7. Aspirating 20 µL of eluent. 
8. Incubation for 10 minutes. 
9. Dispensing 20 µL (eluent) into an Eppendorf tube cap. 
10. Turning the acoustic trap off. 
11. Dispensing 20 µL of the fluid medium, along with the cells, into an Eppendorf 
tube cap with maximum flow rate. 
12. Rinsing the capillary by thrice dispensing 20 µL of the fluid medium with 
maximum flow rate. 
 
The samples were stored overnight in a refrigerator and ISET pretreated according to 
the procedure below (direct ISET, Figures 6 and 7). The solid phase used was a 20 
mg/mL suspension of Poros R2 50 reversed phase beads, and the matrix was 5 mg/mL 
CHCA in 60 % acetonitrile. For liquid transport through the ISET, vacuum of 10 lnHg 
was used at 1-4 and 1.5 lnHg at 6. The sample spots were analyzed with a MALDI-
Orbitrap XL from Thermo Scientific (Waltham, MA, USA) with a 337.1 nm nitrogen 
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UV laser, operated in SIM mode with the resolution of 100000. The settings were 
optimized before data acquisition.  
 
1. Transferring solid phase beads into nanovials. 
2. Transferring 10 µL of sample per nanovial. 
3. Incubating for 15 minutes. 
4. Washing with 2.5 µL of 0.1 % TFA. 
5. Drying the ISET plate bottom with a laboratory wipe. 
6. Eluting thrice with 0.5 µL of matrix, with 15 minutes drying time. 
 
 
Figure 11: The overall procedure used for the screening of cell-drug interactions. A 
cluster of cells is acoustically trapped by aspirating cell suspension into the capillary 
and washing away the untrapped cells, followed by the aspiration of the drug sample 
solution, and incubation. After the incubation of the cells with the drug sample solution, 
the unbound drug sample is removed, and the eluent is aspirated. After the incubation 
with the eluent, the eluent and the fluid medium aliquot (along with the cells) are 
dispensed separately, followed by ISET sample preparation and MALDI MS analysis. 
 
Experiment I. The same procedure as in experiment H, presented above and in Figure 
11, was applied also without using any cells, using 50 µmol/L citalopram or 50 µmol/L 
fluoxetine, 50 µmol/L fluoxetine-D5 as the sample solution. This blank experiment was 
conducted in order to investigate the extent of drug adsorption to the capillary walls, 
and its effect on the analyte signal intensity in the mass spectra. 
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Experiment J. The binding of citalopram, fluoxetine and fluoxetine-D5 to serotonin 
transporter (SERT) in the cell membrane preparation from cells overexpressing SERT 
was investigated according to the procedure presented in experiment H (Figure 11), 
with the following alteration: the first of the three 20 µL fluid medium aliquots used to 
rinse the capillary was not discarded, and an additional 20 µL fluid medium aliquot was 
dispensed after the rinsing, and saved. Both of these aliquots were stored, ISET 
pretreated and analyzed in a similar manner as the actual samples. This was done in 
order to investigate the efficacy of the capillary rinsing procedure conducted between 
individual experiments. The sample solutions used were 50 µmol/L citalopram and 50 
µmol/L fluoxetine, 50 µmol/L fluoxetine-D5. 1:9 ACN:TBS was used as the eluent. 
 
Experiment K. The binding of citalopram and fluoxetine to serotonin transporter in the 
cell membrane preparation was investigated according to the procedure presented in 
experiment H (Figure 11), with the following alteration: after dispensing the cell 
membrane residue, the capillary was rinsed by dispensing 20 µL, aspirating and 
dispensing 20 µL of methanol, and dispensing 20 µL twice. Only the last aliquot was 
discarded, whereas the others were pretreated and analyzed in the same manner as the 
actual samples. Before the sample preparation and analysis, the methanol aliquots were 
evaporated to dryness and the residue dissolved into 20 µL of TBS. Five different 
sample solutions were used: 1 µmol/L fluoxetine; 1 µmol/L citalopram; 1 µmol/L 
fluoxetine, 1 µmol/L citalopram; 1 µmol/L fluoxetine, 100 µmol/L citalopram; 100 
µmol/L fluoxetine, 1 µmol/L citalopram. The same procedure was performed also as a 
blank without any cell membranes, in order to investigate the extent of analyte 
adsorption to the walls of the capillary with each sample solution used. 
 
Experiment L. The suitability of the acoustic trapping system for the screening of 
serotonin transporter activity in platelets was investigated according to the procedure 
below. The platelets were pre-incubated for 10 minutes in the acoustic trap with the 
sample solution, followed by 10 minutes incubation with either 50 µmol/L serotonin 
solution or blank, and cell lysis with 70 % formic acid in MQ water. The sample 
solutions used were 50 µmol/L citalopram and 50 µmol/L fluoxetine, 50 µmol/L 
fluoxetine-D5. The samples were stored, ISET pretreated and analyzed as described in 
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experiment H (Figure 11). In addition, the behavior of serotonin in MALDI MS was 
investigated by dried droplet analysis of 1 mg/mL standard solutions of serotonin and 
the SSRIs used. Sample volume was 0.5 µL and matrix (5 mg/mL CHCA in 60 % 
ACN) volume 1 µL. 
 
Experiment M. The same procedure as in experiment L was repeated with the 
following alteration: before cell lysis, 20 µL of eluent was aspirated into the capillary, 
incubated for 10 minutes with the platelets, dispensed into an Eppendorf tube cap, and 
the remaining eluent was removed by dispensing 60 µL. This was done in order to 
investigate that if serotonin is visible in the spectra, whether it is really transported into 
the cells or merely bound to the cell membrane. The samples were stored, ISET 
pretreated and analyzed as described in experiment H.  
 
3.1.6 Comparative drug binding experiments without acoustic trapping 
 
Experiment N. For comparison with the drug binding studies using acoustic trapping, 
drug binding studies without acoustic trapping were performed using the cell membrane 
preparation from cells overexpressing SERT. Vacuum filtration with a SilentScreen 96-
well filter plate (Nalge Nunc International, Penfield, NY, USA) with Nylon filtering 
membrane (pore size 0.45 µm) was used for the procedure (Figure 12). Similar sample 
solutions as in experiment K were used. With the 1 µmol/L fluoxetine, 1 µmol/L 
citalopram sample solution, no SERT cell membranes were used. This blank experiment 
was done in order to study the extent of drug adsorption to the filtering membrane. 
Before the experiment, the cell membrane preparation was diluted with TBS in a ratio 
of 1:7. The procedure was as presented below. 
 
1. Transferring 40 µL of the SERT cell membrane suspension into a well. 
2. Adding 100 µL of the drug sample solution into the well. 
3. Incubation for 2 hours continuously shaking. 
4. Removing the sample solution through the filtering membrane by vacuum 
suction. 
5. Washing 5 times with 150 µL of Tris hydrochloride 50 mmol/L (pH = 7.4) in 
0.9 % NaCl with similar vacuum suction. 
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6. Removing and discarding the washing waste. 
7. Drying in 50 °C for 40 minutes. 
8. Elution 3 times with 70 µL of methanol. 
9. Evaporation of the methanol overnight in 30 °C. 
10. Dissolving the residues in 40 µL of 0.5 % TFA in MQ water. 
 
 
Figure 12: The vacuum filtration method for the screening of interactions between 
SERT cell membranes and SSRI drugs. The SERT cell membranes are incubated with 
the drug sample solutions in a microwell, followed by the removal of unbound drug by 
washing five times with buffer solution. After this, the analytes are eluted and the eluent 
sample is pretreated and analyzed. 
 
The samples were ISET pretreated according to the procedure presented below (indirect 
ISET, Figure 7). For liquid transport through the ISET, vacuum of 10 lnHg was used at 
phases 3-5 and 1.5 lnHg at phase 6. The sample spots were analyzed with a MALDI-
Orbitrap XL from Thermo Scientific (Waltham, MA, USA) with a 337.1 nm nitrogen 
UV laser, operated in SIM mode with the resolution of 100000. The settings were 
optimized before data acquisition. 
 
1. Addition of 2 µL of Poros R2 50 bead suspension (20 mg/mL) into the wells. 
2. Incubation for 1.5 hours. 
3. Transferring the sample-bead suspension onto ISET plate as 20 µL duplicates. 
4. Drying the ISET plate bottom with a laboratory wipe. 
5. Washing with 2.5 µL of 0.1 % TFA in MQ water. 
6. Eluting thrice with 0.5 µL of matrix solution (5 mg/mL CHCA in 60 % 
acetonitrile), with 15 minutes drying time. 
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3.2 Results and discussion 
 
3.2.1 General 
 
The performance of a new nanobiotechnology platform for the screening of cell-drug 
interactions using acoustic trapping and MALDI MS was studied. The core of the 
platform is the immobilization of cells with acoustic trapping in a fluid-filled 
borosilicate glass capillary (Figures 2 and 8). Acoustic trapping provides a means to 
hold the cells stationary while the fluid in the capillary is moved, allowing the in-trap 
incubation of trapped cells with different sample solutions, and the consequent elution 
of the sample from the cells (Figure 11). The technique of acoustic trapping utilizes an 
ultrasound standing wave, generated by a piezoelectric transducer, to create acoustic 
potential minima and maxima in the fluid medium (Evander and Nilsson 2012). In a 
water-based fluid medium, the cells gather to the acoustic potential minimum, the 
acoustic trap. A more thorough description of acoustic trapping is presented in chapter 
2.2.  
 
In this study, human platelets were used as the cells and selective serotonin reuptake 
inhibitors (SSRI) drugs as the ligands: serotonin transporter (SERT), the molecular 
target of the SSRI drugs, is naturally expressed on the platelets’ cell membranes. Other 
experiments involved similar in-trap incubation of strong cation exchange beads, yeast 
cells, and cell membranes from cells overexpressing human SERT, with the SSRI drugs. 
Sample preparation was done with Integrated Selective Enrichment Target (ISET, 
Figures 6 and 7), a miniaturized solid phase extraction method developed by Ekström et 
al. (2004, 2006). The final analysis read-out was done with MALDI MS. 
 
The ISET sample preparation procedure was optimized using fluoxetine and fluoxetine-
D5 sample solutions of different concentrations. This was done in order to find a 
repeatable and effective method for sample preparation in the experiments to be done. 
Different kinds of solid phase extraction beads were tested, and procedures involving 
incubation of the beads with the sample solution before (indirect ISET) and after (direct 
ISET) transferring them onto the ISET plate were compared (Figure 7). 
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The next experiments involved testing of different piezoelectric transducers in the 
acoustic trapping of polystyrene beads with different fluid medium flow rates. The goal 
of these experiments was to investigate the functional differences of the piezoelectric 
transducers during acoustic trapping and to find a good transducer for the acoustic 
trapping experiments with cells. 
 
Before experimenting with cells, the procedure involving acoustic trapping, ISET 
sample preparation and MALDI MS analysis was modeled using strong cation exchange 
beads instead of cells. Sample solutions with different concentrations of fluoxetine and 
fluoxetine-D5 were used. The sufficient in-trap incubation time of the beads with the 
sample solution and the eluent, and the suitable flow rate of the fluid medium were 
explored. The analysis involving ISET preparation was compared to analysis with dried 
droplet method from a conventional MALDI plate. 
 
Finally, the corresponding experiments involving acoustic trapping, ISET sample 
preparation and MALDI MS analysis (Figure 11) were conducted with yeast cells, 
human platelets and cell membranes from cells overexpressing human serotonin 
transporter. The analyte elution efficiency of different eluents was compared, and the 
suitability of yeast cells to be used as a control experiment for nonspecific SSRI binding 
was investigated. Fluoxetine, fluoxetine-D5 and citalopram sample solutions of 
different concentrations were used. The role of analyte adsorption to the trapping 
capillary and the extent of sample carry-over effect were investigated by conducting the 
same experiments also with an empty acoustic trap (blank). Comparative SSRI binding 
experiments without acoustic trapping were conducted using the cell membrane 
preparation. The suitability of the system for the measurement of serotonin transporter 
activity in platelets was experimented: the platelets, pre-incubated in-trap with SSRI or 
blank, were incubated in-trap with a solution of serotonin, followed by cell lysis and 
MALDI MS analysis. 
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3.2.2 Sample preparation optimization 
 
In order to optimize the ISET sample preparation procedure (Figures 6 and 7) for 
fluoxetine, the performance of two different solid phases, Poros R1 50 and Poros R2 50 
reversed phase beads, in the ISET sample preparation of fluoxetine and fluoxetine-D5 
standard solutions was compared. Direct ISET, in which the solid phase is transferred 
into the ISET chip before introducing the sample solution, was used (Figure 7); the 
experimental procedure is presented in experiment A. The lowest amount of analyte 
yielding signals in the mass spectra was 1.25 pmol for both fluoxetine and fluoxetine-
D5. Slightly more intensive signals were achieved with Poros R2 50 reversed phase 
beads. 
 
Comparison between Poros R1 50 and Poros R2 50 reversed phase beads was done also 
using the indirect ISET, in which the solid phase beads are incubated with the sample 
solution prior to transferring into the ISET plate (Figure 7). The experimental procedure 
was done according to experiment B. Like with the direct ISET protocol, the lowest 
amount of analytes yielding signals was 1.25 pmol, and the intensity of the signals was 
slightly larger with Poros R2 50. 
 
In order to compare the performance of direct and indirect ISET (Figure 7) in the solid 
phase extraction of fluoxetine, the mass spectra from experiment A and experiment B 
were compared. More intensive signals were achieved with indirect ISET, in agreement 
with previous research (Adler et al. 2012). However, the comparison should be done 
with caution: longer incubation time was used with indirect ISET (45 minutes) than 
with direct ISET (15 minutes). In further experiments, indirect ISET was used when 
possible due to the higher signal intensities obtained. All further experiments were 
conducted using Poros R2 50 solid phase beads. 
 
The amount and size of matrix-analyte co-crystals around separate sample spots on the 
backside of the ISET plate (formed during the elution with the eluent solution 
containing the matrix compound, Figure 6) varied, but the effect of the variation on the 
analyte signal intensity is not straightforward: some analyte signals obtained from 
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seemingly poorly crystallized spots were more intensive than other analyte signals from 
seemingly well crystallized spots. This phenomenon is to a large extent a result of the 
MALDI process where “sweet spots” and ion suppression effects easily can lead to 
signal variations of ± 50 % within the same spot (Dreisewerd 2003). It should also be 
noted that any solid phase extraction sample preparation without the use of an internal 
standard will not be quantitative. For these reasons, the ISET sample preparation 
method used is semi-quantitative at its best. 
 
3.2.3 Piezoelectric transducer testing and acoustic trapping capacity 
 
In order to investigate the acoustic trapping differences between piezoelectric 
transducers (Figure 8), 13 transducers of the same batch were tested by filling the 
acoustic trap with 10 µm polystyrene beads and inspecting the maximum tolerated fluid 
flow rate before the bead cluster was flushed out of the acoustic trap (experiment C). 
The testing revealed big variations between transducers in the fluid flow rate that could 
be applied before the bead cluster was lost, ranging from no trapping at all to successful 
trapping at a fluid flow rate 240 µL/min. No visual differences between the transducers 
could be observed. Three transducers (#1, #5 and #8) found to have intermediate to 
good fluid flow rate tolerance, were chosen for further experiments. 
 
Transducers #1, #5 and #8 were further tested by filling the acoustic trap with 3 µm 
polystyrene beads and using Coulter counting to determine the amount of beads that 
could be retained in the acoustic trap at different fluid flow rates (experiment D). 
Figure 13 presents the amounts of 3 µm polystyrene beads trapped by transducers #1, 
#5 and #8 at different fluid flow rates (20-100 µL/min). These measurements revealed 
large variations in trapping capacities for the different transducers. The transducers used 
were manually manufactured, and it can be expected that an industrially manufactured 
kerfed transducer would significantly improve the situation (Hammarström et al. 2014). 
Also variability in the mounting of the capillary above the transducer may affect 
ultrasound transmission. Due to its superior trapping capacity according to this 
experiment, transducer #8 with a fluid flow rate 20 µL/min was chosen for the further 
experiments. 
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Figure 13: Trapping capacities of transducers #1, #5 and #8. The amounts of trapped 
beads at flow rates 20 to 100 µL/min were analyzed using a Coulter counter. 
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3.2.4 Experiment with strong cation exchange beads 
 
The performance of the analytical system, involving acoustic trapping and MALDI MS 
analysis, was tested using strong cation exchange (SCX) beads according to the 
procedure presented in experiment E. SCX beads where chosen to emulate cells 
because they provide a negatively charged surface similar to the platelets (Seaman 
1973). Both aliquots dispensed from the acoustic trap, the eluent aliquots and the fluid 
medium aliquots containing the SCX beads, were analyzed with MALDI MS from a 
conventional MALDI plate (dried droplet analysis). When the 5 µmol/L fluoxetine and 
fluoxetine-D5 sample solution was used, no signals of the analytes were observed. The 
use of 12.5 µmol/L sample solution lead to weak signals in the spectra from the eluent 
aliquots, the strongest signals having approximately S/N = 3 (Figure 14); further 
increasing the sample solution concentration did not increase the analyte signal 
intensities. No analyte signals from the fluid medium aliquots containing the SCX beads 
were observed with any sample solution concentration used. 
 
The efficiency of the indirect ISET sample preparation (Figure 7) was investigated by 
ISET sample preparation and analysis of the remaining eluent aliquots and fluid 
medium aliquots containing the SCX beads from experiment E, according to the 
procedure presented in experiment F. With the eluent aliquots dispensed from the 
acoustic trap, the ISET sample preparation did not improve the sensitivity (comparison 
to the dried droplet analysis from a MALDI plate, described in experiment E, Figure 
14). For the fluid medium aliquots containing the SCX beads, the analysis after ISET 
sample preparation yielded spectra similar to those from the eluent aliquots (Figure 14). 
This indicates that after the elution of fluoxetine and fluoxetine-D5 from the 
acoustically trapped SCX beads, analytes remain on the beads, and thus a more effective 
elution method should be investigated. The SCX beads have most likely been saturated 
with the analytes during the incubation, since the different analyte concentrations in the 
sample solutions (except the most dilute) lead to no difference in analyte signal 
intensities in the spectra. If bead saturation occurs, the sensitivity can’t be improved by 
using a longer incubation time with the sample solution. Longer incubation times would 
also make the process inconveniently slow. 
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Figure 14: MALDI MS spectra from 1 µm SCX beads incubated for 30 minutes in-trap 
with 12.5 µmol/L of fluoxetine (m/z ≈ 310) and fluoxetine-D5 (m/z ≈ 315). The flow 
rate was 20 µL/min. a) eluent aliquot, dried droplet analysis from a MALDI plate; b) 
eluent aliquot, analysis after ISET sample preparation; c) fluid medium aliquot 
containing the SCX beads, analysis after ISET sample preparation. 
 
3.2.5 Drug binding experiments using acoustic trapping 
 
First, the yeast cell suspension, platelet rich plasma (PRP), and cell membrane 
suspension volumes needed to fill the acoustic trap with cells or cell membranes were 
investigated (experiment G). In addition, it was examined whether the acoustically 
trapped cluster of cells or cell membranes remains in the acoustic trap during the 
aspiration of different eluents. For yeast cell suspension, PRP, and cell membrane 
suspension, the aspiration volume of 40 µL was sufficient to fill the acoustic trap with 
cells or cell membranes. It was found that acetonitrile (ACN) or methanol percentage 
exceeding 25 % in the eluent caused the failure of the acoustic trapping of platelets even 
at flow rates as low as 10 µL/min, due to the large change in the acoustic properties of 
the fluid. The acoustically trapped yeast cells were more resistant to high organic 
solvent percentage in the eluent than the platelets, remaining trapped during the 
aspiration of eluents with up to 50 % organic solvent. With the other eluents (0.5 % 
TFA in MQ water and 10 mmol/L glycine in MQ water acidified to pH ≈ 2 with 
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hydrochloric acid), the acoustic trapping of both yeast cells and platelets was successful 
with all flow rates tested. The trapped cluster of cell membranes remained within the 
acoustic trap during the aspiration of the eluent 1:9 ACN:TBS (10 % acetonitrile in 
Tris-buffered saline) with the flow rate 20 µL/min. The organic solvent -containing 
eluent chosen for further experiments with yeast cells and platelets was 1:9 ACN:PBS 
(10 % acetonitrile in phosphate buffered saline), because successful acoustic trapping of 
both yeast cells and platelets with the same eluent was required. Also the ISET sample 
preparation step requires sufficiently low organic solvent percentage, as the presence of 
organic solvent would decrease the binding of analytes to the hydrophobic solid phase. 
For the cell membrane preparation, the eluent 1:9 ACN:TBS was used in further 
experiments. 
 
In the following experiments, MALDI MS was used for semiquantitative analysis: the 
analyte signal intensities were compared to matrix signal intensities in the mass spectra 
(fluoxetine: m/z = 310.14 compared to m/z 310.07; fluoxetine-D5: m/z = 315.17 
compared to m/z 315.08; citalopram: m/z = 325.17 compared to m/z = 324.32). In this 
paper, these ratios are referred to as matrix-relative signal intensities, and presented in 
the corresponding figures (Figures 15-21). It has to be kept in mind that due to the poor 
repeatability of the MALDI desorption and ionization process (Dreisewerd 2003), 
comparison should be done with caution, and the results be regarded as semiquantitative 
at best. 
 
The elution efficiency of three different eluents (1:9 ACN:PBS, 0.5 % TFA in MQ 
water, and 10 mmol/L glycine in MQ water acidified to pH ≈ 2 with hydrochloric acid) 
was investigated by incubating yeast cells or platelets in the acoustic trap with a sample 
solution containing 50 µmol/L of both fluoxetine and fluoxetine-D5, and eluting with 
the eluent, according to the procedure presented in experiment H. The same 
experiment was used to determine the suitability of yeast cells to be used as a model for 
nonspecific binding of the analytes to the cell membranes. For both yeast cells and 
platelets, eluting with ACN:PBS 1:9 was found to lead to most intensive analyte signals 
(Figures 15 and 16). Also the approximate ratio between the intensities of the signals 
from the eluent aliquots and the signals from the fluid medium aliquots containing the 
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cells (dispensed from the capillary after the elution) was highest with the eluent 
ACN:PBS 1:9, suggesting the most effective elution of the analytes (Figures 15 and 16). 
Surprisingly, the analyte signals from platelets were less intensive than those from yeast 
cells, despite that the yeast cells lack serotonin transporter. This difference in the signal 
intensities was greater in the fluid medium aliquots containing the cells, implying more 
efficient analyte elution from the platelets than the yeast cells. Another SSRI drug, 
sertraline, has been reported to accumulate in cell membranes and other organelles in 
yeast cells (Chen et al. 2012), and this may be the case for fluoxetine as well. The 
fluoxetine accumulation to the cell membranes could explain the less efficient elution of 
fluoxetine from the yeast cells: analytes accumulated to cell membranes are less readily 
eluted than specifically bound analytes. According to these results, ACN:PBS 1:9 was 
the most effective eluent for eluting fluoxetine from both yeast cells and platelets. Yeast 
cells were abandoned as a control due to the high nonspecific binding observed. 
 
 
Figure 15: The mass spectra and the matrix-relative signal intensities from yeast cells 
incubated with an SSRI drug sample solution (50 µmol/L of both fluoxetine and 
fluoxetine-D5) and eluted with the eluent ACN:PBS 1:9. a) eluent aliquot; b) fluid 
medium aliquot containing the cells. The protonated molecular ions of fluoxetine (m/z = 
310.14) and fluoxetine-D5 (m/z = 315.17) are written with red font. 
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Figure 16: The mass spectra and the matrix-relative signal intensities from platelets 
incubated with an SSRI drug sample solution and eluted with the eluent ACN:PBS 1:9. 
a) and b) 50 µmol/L fluoxetine, 50 µmol/L fluoxetine-D5, eluent aliquot; c) and d) 50 
µmol/L fluoxetine, 50 µmol/L fluoxetine-D5, fluid medium aliquot containing the 
platelets; e) 50 µmol/L citalopram, eluent sample aliquot; f) 50 µmol/L citalopram, fluid 
medium aliquot containing the platelets. The protonated molecular ions of fluoxetine 
(m/z = 310.14), fluoxetine-D5 (m/z = 315.17) and citalopram (m/z = 325.17) are written 
with red font. 
 
In experiment H, the same procedure involving acoustic trapping, ISET sample 
preparation and MALDI MS analysis was used to investigate the binding of citalopram 
to platelets as well. The behavior of citalopram was confirmed to be similar to 
fluoxetine and fluoxetine-D5: clearly distinguishable signals of citalopram were present 
in the spectra from both the eluent aliquots and the fluid medium aliquots containing the 
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cells (Figure 16, e and f). According to the results of Experiment H, a more efficient 
elution method should be investigated. The high signal intensity of citalopram in the 
spectrum from the fluid medium aliquot containing the platelets suggests either poor 
elution of citalopram from the platelets or, more likely, citalopram carry-over. 
 
The results from experiment H can’t be used to estimate whether the analyte signals in 
Figures 15 and 16 arise from analytes bound to the cells and eluted from them, or from 
analytes adsorbed to the trapping capillary walls and eluted from them. In order to 
investigate the extent of drug adsorption to the walls of the capillary used for acoustic 
trapping, the same acoustic trapping procedure presented in experiment H was applied 
also with an empty acoustic trap, without using any cells (blank, experiment I). In the 
spectra from eluent aliquots dispensed from the trapping capillary, the analyte signal 
intensities relative to matrix signal intensities of the analytes were less intensive than in 
the experiments with cells (Figure 17). For fluoxetine and fluoxetine-D5, these analyte 
signal intensities were on the same scale as those from the fluid medium aliquots 
containing the platelets in experiment H (Figure 16), but for citalopram, the signal 
intensity was significantly higher, possibly due to either carry-over in the trapping 
capillary or contamination on the ISET plate used for sample preparation. These results 
suggest that a small portion of the analyte signals in the spectra in experiment H 
(Figures 15 and 16) arises from the analytes adsorbed to the capillary walls and 
desorbed during the elution process, but the analytes bound to the cells and desorbed 
from them are responsible for the majority of the signals. The capillary is manufactured 
of borosilicate glass, for which low tendency to adsorb drug compounds (compared to 
other types of glass) is typical (Marchal-Heussler and Barra 2006). However, the 
concentrations of fluoxetine, fluoxetine-D5 and citalopram in the sample solutions were 
so large (50 µmol/L) that adsorption can’t be avoided. Lower drug concentrations in the 
sample solutions should thus be used, if the sensitivity of the MALDI MS detection 
allows. 
 
Due to the analyte adsorption to the capillary in experiment I, lower drug concentration 
(1 µmol/L fluoxetine or citalopram) in the sample solution was used for similar blank 
measurements. This was done during experiment K. The mass spectra from the eluent 
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aliquots are presented in Figure 18. As expected, the signal intensity of fluoxetine was 
lower than with the 50 µmol/L sample, but still clearly detectable. The signal intensity 
of citalopram was extremely high, indicating excessive carry-over contamination. 
 
 
Figure 17: The mass spectra and the matrix-relative signal intensities from the empty 
acoustic trap (blank) incubated with an SSRI drug sample solution and eluted with the 
eluent ACN:PBS 1:9. a) and b) 50 µmol/L fluoxetine, 50 µmol/L fluoxetine-D5, eluent 
aliquot; c) 50 µmol/L citalopram, eluent aliquot. The protonated molecular ions of 
fluoxetine (m/z = 310.14), fluoxetine-D5 (m/z = 315.17) and citalopram (m/z = 325.17) 
are written with red font. 
 
Figure 18: The mass spectra and the matrix-relative signal intensities from the empty 
acoustic trap (blank) incubated with an SSRI drug sample solution and eluted with the 
eluent ACN:TBS 1:9. a) 1 µmol/L fluoxetine, eluent aliquot; b) 1 µmol/L citalopram, 
eluent aliquot. The protonated molecular ions of fluoxetine (m/z = 310.14) and 
citalopram (m/z = 325.17) are written with red font. 
 
In experiment I, 20 µL aliquots of the fluid medium (equivalent to the fluid medium 
aliquots containing the cells in experiments with cells) were dispensed from the 
capillary after dispensing the eluent. ISET sample preparation and MALDI MS analysis 
was done to these aliquots in order to investigate whether there are residual analytes 
adsorbed to the capillary after the elution. Signals of fluoxetine, fluoxetine-D5 and 
citalopram were present also in these aliquots (data not shown), which suggests that the 
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elution may not be enough to remove all of the adsorbed analytes from the capillary, 
leading to carry-over effects. 
 
Due to the carry-over contamination effects appearing in experiment I, the efficiency 
of the capillary rinsing between individual experiments was investigated by ISET 
pretreating and analyzing the fluid medium aliquots dispensed from the capillary after 
rinsing the capillary between individual experiments. This was done during experiment 
J. The analysis revealed the inadequacy of the capillary rinsing process, as some 
residual analyte signals were visible in the mass spectra, citalopram with greater 
intensity than fluoxetine or fluoxetine-D5 (Figure 19). This result, implying citalopram 
carry-over, may explain the presence of citalopram signals in the spectra from the 
measurements in which no citalopram was used. 
 
 
Figure 19: The mass spectra and the matrix-relative signal intensities of 20 µL fluid 
medium aliquots dispensed from the capillary after rinsing the capillary, showing the 
signals of fluoxetine (m/z = 310.14), fluoxetine-D5 (m/z = 315.17) and citalopram (m/z 
= 325.17). 
 
Since the capillary rinsing with the fluid medium only was proven to be insufficient, it 
was investigated whether rinsing the capillary by aspirating and dispensing 20 µL of 
methanol between individual experiments would reduce the capillary contamination. 
After dispensing from the capillary, the methanol aliquots were evaporated to dryness, 
dissolved in 20 µL of the fluid medium, ISET pretreated and analyzed by MALDI MS. 
In addition, 20 µL of the fluid medium was dispensed from the capillary after the 
methanol rinsing (after-rinse aliquots), and these aliquots were ISET pretreated and 
analyzed by MALDI MS as well. This was done during experiment K. The mass 
spectra from the aforementioned methanol and fluid medium aliquots are presented in 
Figure 20. Some of the methanol aliquots, and all of the fluid medium aliquots 
dispensed after rinsing with methanol, lead to weak signals of the analytes in the mass 
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spectra (Figure 20). This suggests that the rinsing process applied between individual 
experiments is not sufficiently efficient. The absence of signals in some of the spectra 
obtained from the methanol aliquots can be explained by incomplete analyte dissolution 
after the evaporation of methanol. A more efficient rinsing procedure or a surface 
inactivation method for the capillary should be examined. Another alternative would be 
to replace the capillary between individual experiments. 
 
 
Figure 20: The mass spectra and the matrix-relative signal intensities of the methanol 
aliquots, evaporated to dryness and the residue dissolved in the fluid medium, and fluid 
medium aliquots, dispensed from the capillary after the methanol rinsing. a) methanol 
aliquot, sample solution 1 µmol/L fluoxetine; b) after-rinse aliquot, sample solution 1 
µmol/L fluoxetine; c) methanol aliquot, sample solution 1 µmol/L citalopram; d) after-
rinse aliquot, sample solution 1 µmol/L citalopram. The protonated molecular ions of 
fluoxetine (m/z = 310.14) and citalopram (m/z = 325.17) are marked with red font. 
 
According to the results concerning analyte adsorption to the capillary (Figures 17 to 
20), citalopram seems to have excessive tendency to adsorb to the capillary and cause 
carry-over contamination. Due to this, citalopram appears not to be well suited for this 
method, and other SSRIs should thus be used in future experiments. 
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The serotonin transporter (SERT) expression level in human platelets is 2.5 pmol/mg 
membrane protein (Wall et al. 1993). In order to achieve higher intensity analyte signals 
in the mass spectra, a cell membrane preparation with SERT expression level of 6.8 
pmol/mg membrane protein (“SERT cell membranes”) was used instead of platelets. 
The binding of citalopram, fluoxetine and fluoxetine-D5 (all 50 µmol/L) to SERT in the 
cell membrane preparation was investigated according to the procedure presented in 
experiment J. As expected, the analysis of the eluent aliquots and the fluid medium 
aliquots containing the cell membranes, both dispensed from the acoustic trap, showed 
analyte signal intensities larger than in the measurements with platelets in experiment 
H (Figure 21). The higher expression of SERT, and the consequent higher amount of 
specifically bound SSRI, in the cell membrane preparation than in platelets is the most 
likely explanation for the more intensive analyte signals observed with the cell 
membrane preparation. Comparison to platelets was done because of the possible 
difference in acoustic trapping capacity of SERT cell membranes and platelets. The 
corresponding mass spectra for citalopram are not presented, because the signal of 
citalopram was present in most of the mass spectra, due to the memory effect discussed 
above. 
 
The specific and nonspecific binding of fluoxetine to the SERT cell membranes were 
investigated according to the procedure presented in experiment K: the acoustically 
trapped SERT cell membranes were incubated with the drug sample solution, followed 
by the elution of the analytes, and the consequent ISET sample preparation and MALDI 
MS analysis of the eluent aliquot. Five sample solutions, as listed in the Materials and 
methods section, were used, but due to the citalopram memory effect discussed above, 
only the following two of them were compared: 
 
1. 1 µmol/L fluoxetine (total binding of fluoxetine) 
2. 1 µmol/L fluoxetine, 100 µmol/L citalopram (nonspecific binding of fluoxetine) 
 
With sample solution 1, fluoxetine binds to the SERT cell membranes both specifically 
and nonspecifically, whereas with sample solution 2, the citalopram present in excess 
was used to saturate the SERT in the cell membranes, leading to only nonspecific 
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binding in the case of fluoxetine. Similar approach to study nonspecific binding of SSRI 
drugs to SERT has been successfully used by Hess et al. (2011). The fluoxetine mass 
spectra of the eluents from SERT cell membranes incubated with drug sample solutions 
1 and 2 are presented in Figure 22. Though there is a 4-fold difference in fluoxetine 
signal intensity between the spectra from the experiments with sample solutions with 
(Figure 22, a) and without (Figure 22, b) 100 µmol/L citalopram in them (representing 
the nonspecific binding and the total binding, respectively), it is not straightforward to 
estimate whether the difference is due to the fluoxetine binding to SERT or only 
uncertainty arising from the ISET sample preparation and the MALDI MS 
measurement. Fluoxetine adsorption to the capillary is a factor that complicates the 
assessment of the extent of nonspecific binding. From the data in Figures 16, 17 and 21, 
it seems like nonspecific binding and analyte adsorption to the capillary have similar 
signal intensities, accounting for approximately 10 % of the signals observed in the 
eluent samples. 
 
The suitability of the system involving acoustic trapping, ISET sample preparation and 
MALDI MS analysis for the screening of serotonin transporter activity in platelets was 
investigated as described in experiment L and experiment M: the platelets were 
preincubated with SSRI solution or blank (fluid medium), followed by incubation with a 
serotonin solution and cell lysis. The approach was not successful, since serotonin could 
not be detected from the sample aliquots dispensed from the trapping capillary. The 
poor ionization properties of serotonin in MALDI MS were confirmed by analyzing 1 
mg/mL stock solution of serotonin co-crystallized with a matrix solution on a MALDI 
plate. A different ionization method, such as electrospray ionization (ESI), should be 
tested for direct measurements of serotonin. 
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Figure 21: The mass spectra and the matrix-relative signal intensities of SERT cell 
membrane samples incubated with a solution containing 50 µmol/L of both fluoxetine 
and fluoxetine-D5 and eluted with the eluent ACN:TBS 1:9: a) eluent aliquot; b) fluid 
medium aliquot containing the cell membranes. The protonated molecular ions of 
fluoxetine (m/z = 310.14) and fluoxetine-D5 (m/z = 315.17) are written with red font. 
 
 
Figure 22: The mass spectra and the matrix-relative signal intensities of eluent aliquots 
from the experiment K: a) sample solution fluoxetine 1 µmol/ (total binding); b) 
sample solution fluoxetine 1 µmol/L, citalopram 100 µmol/L (nonspecific binding). The 
protonated molecular ion of fluoxetine (m/z = 310.14) is marked with red font. 
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3.2.6 Comparative drug binding experiments without acoustic trapping 
 
For comparison with the drug binding studies using acoustic trapping, the binding of 
fluoxetine and citalopram to serotonin transporter (SERT) in the cell membrane 
preparation from cells overexpressing SERT (“SERT cell membranes”) was 
investigated without acoustic trapping, using vacuum filtration (Experiment N, Figure 
12). The following sample solutions were used: 1 µmol/L fluoxetine; 1 µmol/L 
citalopram; 1 µmol/L fluoxetine, 1 µmol/L citalopram; 1 µmol/L fluoxetine, 100 
µmol/L citalopram; 100 µmol/L fluoxetine, 1 µmol/L citalopram. The choice of the 
sample solutions was done in order to investigate nonspecific drug binding to cell 
membranes, in a similar manner as in experiment K. Blank measurements without cell 
membranes were conducted in order to assess the binding of fluoxetine and citalopram 
to the filtering membranes. The sample preparation was done with indirect ISET (Figure 
7). The mass spectra from the eluent samples are presented in Figure 23. The spectra of 
citalopram are shown, because for an unknown reason, the corresponding fluoxetine 
spectra showed no signals of fluoxetine, and could not be used for comparison with 
experiment K (Figure 22). 
 
These results indicate that the magnitudes of both nonspecific binding (Figure 23, c) 
and analyte adsorption to the filtering membrane (Figure 23, d) are below the detection 
limit of the system, since no signals of citalopram are present in the spectra. Another 
alternative is the failure of the method, since the amount of SERT cell membranes used 
should lead to detectable amounts of citalopram. According to these results, the acoustic 
trapping method for screening of SSRI binding to SERT cell membranes was more 
successful than the vacuum filtration method, but the comparison should be made with 
care: significantly more optimization was done with the acoustic trapping method. In 
addition, a method involving vacuum filtration and mass spectrometry has been 
successfully used for a fluoxetine-SERT binding assay (Hess et al. 2011). It has to be 
noted that with these results, direct comparison of the acoustic trapping method in 
experiment K and the vacuum suction method is not justifiable, given the different cell 
membrane preparation and sample solution amounts used. 
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Figure 23: The mass spectra of citalopram from experiment N. a) SERT cell 
membranes, solvent blank; b) SERT cell membranes, sample solution 1 µmol/L 
citalopram (total binding); c) SERT cell membranes, sample solution 1 µmol/L 
citalopram, 100 µmol/L fluoxetine (specific binding); d) blank, sample solution 1 
µmol/L citalopram, 1 µmol/L fluoxetine (adsorption to filtering membrane). The 
protonated molecular ion of citalopram (m/z = 325.17) is marked with red font. 
 
3.2.7 Critical assessment of the method performance 
 
Throughout the experiments, solvent blank experiments were conducted in addition to 
the experiments in which real fluoxetine, fluoxetine-D5 or citalopram samples were 
used. This was done in order to confirm that the buffer solutions and the eluents were 
free of the analytes. However, in many (but not all) of the mass spectra from the solvent 
blank experiments, weak signals of the analytes were present. According to the blank 
measurements in experiment I and experiment J, analyte adsorption to the walls of the 
borosilicate glass capillary used for acoustic trapping is detectable, and according to 
experiment J and experiment K, the procedure used for rinsing the capillary between 
individual experiments was not adequate. For these reasons, it can be assumed that 
analyte carry-over from the capillary is an issue of concern. To decrease analyte 
adsorption to the capillary, surface inactivation could be used. In addition, the signal of 
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citalopram was present in all spectra in experiment J and experiment K, which 
suggests ISET plate contamination, since the samples were pretreated with the same 
ISET plate. Thus, the main drawback of the analytical platform investigated was the 
carry-over effect. Mass-production of disposable capillaries and ISET plates would 
eliminate the problem, but also increase the price. More rounds of cleaning could be 
used, but this would make the method more time-consuming. 
 
Another main drawback of the system investigated was sensitivity: in order to achieve 
analyte signals in the spectra, high analyte concentrations were required, which lead to 
high adsorption of the analytes to the capillary walls (experiment I, experiment J). 
According to the results of experiment D, the acoustic trapping capacity for transducer 
#8 is approximately 1000000 polystyrene beads of the diameter 3 µm. The platelet 
diameter being approximately the same (Paulus 1975), roughly the same value for 
trapping capacity can be assumed also for platelets. The SERT amount of 9 pmol/mg 
membrane protein corresponds to 500000 copies/cell (Tate and Blakely 1994). In 
platelets, the SERT amount is 2.5 pmol/mg membrane protein (Wall et al. 1993), giving 
roughly 200 fmol of SERT per 10
6
 platelets in the acoustic trap. According to this 
calculation, the maximum amount of SSRI drug specifically bound to SERT in the 
acoustically trapped platelet cluster is approximately 200 fmol, which is challenging for 
the mass spectrometric detection. However, the actual amount of platelets trapped may 
differ from that of the polystyrene beads, given the different shape and compressibility 
of platelets. Consequently, even large uncertainty in the calculation can be assumed. 
 
Improved sensitivity might be achieved using LC-ESI-MS/MS, as done by Hess et al. 
(2011). Alternatively, larger size of the apparatus could be used to increase the amount 
of cells trapped, and thus decrease the sensitivity requirement. However, this can be 
done only to some extent, because in overly large system, the advantages of 
microfluidic setup are lost: the flow will be turbulent instead of laminar, and sample and 
energy consumption will be larger. In addition, already with the equipment used, the 
fluid volumes were relatively large to be pretreated with ISET. Larger fluid volumes 
would require the utilization of a different sample preparation method. 
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In order to be useful in drug discovery, the analytical method needs to be fast enough to 
be able to go through large sample libraries in reasonable time. Clearly, with the method 
investigated, the way to achieve this would be parallel systems, as the incubation times 
per one measurement were relatively long. Parallel systems would require unfeasibly 
large numbers of the equipment. The technology required to achieve automatization, on 
the other hand, is not overly complicated: mounting the system on a xyz-stage and using 
pre-programmable syringe and vacuum pumps would permit the automatization of most 
of the phases. 
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4 CONCLUSIONS 
 
In this MSc (Pharm) thesis, a new nanobiotechnology method, involving acoustic 
trapping, miniaturized solid phase extraction sample preparation, and analysis by 
MALDI MS, was described and tested for the screening of cell-drug interactions. The 
sample preparation using the integrated selective enrichment target (ISET) platform was 
optimized for fluoxetine, the selective serotonin reuptake inhibitor (SSRI) drug 
compound used as an analyte. The performance of the acoustic trapping setup was 
investigated both qualitatively and quantitatively. The method was modeled and the 
procedure optimized by using strong cation exchange (SCX) beads for emulating cells. 
The performance of the method in the screening of cell-drug interactions was 
investigated using yeast cells, human platelets, and a cell membrane preparation from 
cells overexpressing serotonin transporter (SERT), the molecular target of the analytes 
used. Comparative experiments without acoustic trapping were performed using 
vacuum filtration. 
 
Within the scope of this work, the performance of the new nanobiotechnology method 
for the screening of cell-drug interactions could not be thoroughly substantiated, despite 
some promising results obtained. The major problems with the method were inadequate 
sensitivity and contamination issues: due to the low sensitivity, high analyte 
concentrations were required, which resulted in analyte adsorption to the platform and, 
consequently, carry-over contamination. The use of a more sensitive tandem mass 
spectrometric method combined with chromatographic separation (LC-ESI-MS/MS) 
could be used to enable the use of less concentrated analyte solutions, thus reducing the 
analyte adsorption to the platform, and the consequent carry-over contamination. 
Further research and method development is required to reliably prove whether or not 
acoustic trapping is suitable for the screening of cell-drug interactions. 
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